ECO Animal Health Group’s (EAH) Buy Rating Reaffirmed at Shore Capital

Shore Capital reaffirmed their buy rating on shares of ECO Animal Health Group (LON:EAH) in a research report report published on Wednesday, MarketBeat.com reports.

ECO Animal Health Group Stock Performance

Shares of EAH stock opened at GBX 118.95 ($1.49) on Wednesday. The company has a debt-to-equity ratio of 4.57, a quick ratio of 2.14 and a current ratio of 3.16. ECO Animal Health Group has a fifty-two week low of GBX 82.67 ($1.04) and a fifty-two week high of GBX 124 ($1.56). The stock has a 50 day moving average price of GBX 94.24 and a two-hundred day moving average price of GBX 102.62. The company has a market capitalization of £80.57 million, a P/E ratio of -6,000.00 and a beta of 0.07.

ECO Animal Health Group Company Profile

ECO Animal Health Group plc, together with its subsidiaries, develops, registers, and markets pharmaceutical products for animals worldwide. The company provides Aivlosin, a macrolide antibiotic for the treatment of enteric and respiratory diseases in pigs and poultry. It also offers generic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic, which are endectocides and other antiparasitics for the treatment and prevention of parasites, such as worms, ticks, mange, and lices in cattle, sheep, pigs, horses, and dogs; and Chlortetracycline and Oxytetracycline for treatment of bacterial infections in pigs, poultry, and cattle.